All In Biotech

Drug Trial Radar · NCT02678689

A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

Last checked: Nov 20, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Jan 22, 2016

Primary completion

Apr 20, 2022

Study completion Apr 20, 2022

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Feb 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.

Conditions

  • Jansky-Bielschowsky Disease
  • Batten Disease
  • Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
  • CLN2 Disease
  • CLN2 Disorder

Interventions

  • BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)Biological

  • Intracerebroventricular access deviceDevice

    Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Motor Language (ML) Scale: Rate of Decline in the 0 to 6-point ML Score.Time frame: Baseline to Last assessment (Week 169)
  2. Probability of Unreversed 2-Point Decline in Motor-language (ML) Score or Score of 0Time frame: Baseline to Last assessment (Week 169)
  3. Probability of Decline of Unreversed Motor-language (ML) Score of 0Time frame: Baseline to Last assessment (Week 169)
  4. Rate of Decline in Individual Motor DomainsTime frame: Baseline to Last assessment (Week 169)
  5. Rate of Decline in Individual Language DomainsTime frame: Baseline to Last assessment (Week 169)

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Children's Hospital Bambino Gesù,IRCCS

    Rome, Piazza, Italy

  • Great Ormond Street Childrens Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.